Invasive Lobular Breast Carcinoma
11
1
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
9%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer